MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Lewy bodies"

  • 2016 International Congress

    Utility of the Mayo sleep questionnaire in predicting final autopsy diagnosis of alpha-synucleinopathy

    D. Shprecher, J. Hentz, C. Adler, B. Dugger, H. Shill, E. Driver-Dunkley, S. Mehta, M. Sabbagh, C. Belden, R. Savica, L. Sue, T. Beach (Sun City, AZ, USA)

    Objective: To ascertain the utility of the MSQ in predicting final autopsy diagnosis of an alpha-synuleinopathy. Background: Idiopathic REM sleep behavior disorder (iRBD) is a…
  • 2016 International Congress

    Safety of nelotanserin in a randomized placebo-controlled phase 2 study

    W. Wen, L. Friedhoff, K. Kishnani, S. Ramaswamy, S. Piscitelli, M. Sanchez, W. Shanahan (New York, NY, USA)

    Objective: To explore the safety of nelotanserin in a phase 2 study in patients with nelotanserin. Background: Nelotanserin is a highly selective and poent inverse…
  • 2016 International Congress

    Effect of nelotanserin on objective sleep parameters in a phase 2 study in patients with insomnia

    W. Wen, L. Friedhoff, K. Kishnani, S. Ramaswamy, M. Sanchez, W. Shanahan (New York, NY, USA)

    Objective: To understand the effects of nelotanserin on objective sleep parameters in a phase 2 study in patients with primary insomnia. Background: Nelotanserin is a…
  • 2016 International Congress

    Examining the clinical profile of nelotanserin, a novel agent in development for Lewy body dementia

    W. Wen, K. Kishnani, S. Ramaswamy, S. Piscitelli (New York, NY, USA)

    Objective: To examine the clinical profile of nelotanserin, a novel agent in development for the treatment of Lewy body dementia. Background: Although not FDA-approved for…
  • 2016 International Congress

    Novel small molecules targeting alpha-synuclein aggregation for the treatment of Parkinson’s disease

    E. Tsika, A. Davranche, E. Gabellieri, S. Nampally, J. Molette, S. Papin, H. Kroth, A. Pfeifer, D. Lowe, A. Muhs (Lausanne, Switzerland)

    Objective: To develop novel, small molecular weight compounds, that can interfere with the aggregation process of alpha-synuclein (aSyn), as disease modifying agents. Background: The aggregation…
  • 2016 International Congress

    Alpha-synuclein aggregates of cardiac sympathetic nerves in synucleinopathies and in neurologically unimpaired subjects. Correlation with sympathetic denervation

    M. Carmona-Abellán, I. Marcilla, I. Martínez-Valbuena, T. Tuñón, R. Luquin-Piudo (Pamplona, Spain)

    Objective: To study the cardiac sympathetic innervation and its relationship with the incidence of alpha-synuclein deposits in heart tissue of synucleinopathies and asymptomatic control patients.…
  • 2016 International Congress

    Identification of Usp8 as a toxicity modifying deubiquitinase for α-synuclein

    Z. Alexopoulou, J. Lang, R. Perrett, H.T. Kim, A.L. Goldberg, O. Ansorge, T.A. Fulga, G.K. Tofaris (Oxford, United Kingdom)

    Objective: To study whether ubiquitination in Lewy bodies is directly relevant to α-synuclein turnover and Parkinson's pathogenesis. Background: In Parkinson's disease, misfolded α-synuclein accumulates, often…
  • 2016 International Congress

    Toward a new biomarker on Parkinson’s disease: Study of alpha synuclein on upper enteric system by endoscopy

    N. Ben Ali, S. Mrabet, S. Hawet, R. Debbiche, S. Belal (Tunis, Tunisia)

    Objective: The aim of our study was to investigate the alpha synuclein deposition at the enteric nerve system on patient with Parkinson's disease and provide…
  • 2016 International Congress

    Alpha-synuclein in gastric and colonic mucosa in Parkinson’s disease: Limited role as a biomarker

    S.J. Chung, J. Kim, H.J. Lee, H.S. Ryu, K.W. Jung, M.J. Kim, M.J. Kim, S.M. Hong, S.J. Myung (Seoul, Korea)

    Objective: We aimed to investigate the utility of alpha-synuclein (α-SYN) immunoreactivity from gastric and colonic mucosal tissues obtained by routine endoscopy to detect Parkinson's disease…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley